Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clyde Markowitz

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Neurology|February 26, 2021
Multifocal neutrophilic meningoencephalitis: a novel disorder responsive to anakinraJoseph R Berger, Clyde Markowitz, Peter A Merkel, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 25, 2020
An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disabilityJerry S Wolinsky, Natalie J Engmann, Jinglan Pei, et al.
BMC Neurology|April 9, 2014
The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosisEdward Fox, Barbara Green, Clyde Markowitz, et al.
BMC Neurology|March 15, 2014
Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomesPatricia K Coyle, Bruce A Cohen, Thomas Leist, et al.
Journal of the Neurological Sciences|August 7, 2002
Optimizing immunomodulatory therapy for MS patients: an integrated management modelDouglas Jeffery, Khurram Bashir, Linda Buchwald, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 13, 2018
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trialEdward J Fox, Clyde Markowitz, Angela Applebee, et al.
Multiple Sclerosis and Related Disorders|July 22, 2015
Relation of quantitative visual and neurologic outcomes to fatigue in multiple sclerosisSalim Chahin, Deborah Miller, Reiko E Sakai, et al.
Annals of Neurology|April 3, 2008
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trialAmit Bar-Or, Peter A J Calabresi, Douglas Arnold, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 10, 2023
Severe Neuroinvasive West Nile Virus in Association With Anti-CD20 Monotherapy for Multiple SclerosisSimon Thebault, Stephanie Gandelman, Camryn Lane, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|August 16, 2023
Intersite brain MRI volumetric biases persist even in a harmonized multisubject study of multiple sclerosisKelly A Clark, Carly M O'Donnell, Mark A Elliott, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Neurology|February 26, 2021
Multifocal neutrophilic meningoencephalitis: a novel disorder responsive to anakinraJoseph R Berger, Clyde Markowitz, Peter A Merkel, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 25, 2020
An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disabilityJerry S Wolinsky, Natalie J Engmann, Jinglan Pei, et al.
BMC Neurology|April 9, 2014
The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosisEdward Fox, Barbara Green, Clyde Markowitz, et al.
BMC Neurology|March 15, 2014
Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomesPatricia K Coyle, Bruce A Cohen, Thomas Leist, et al.
Journal of the Neurological Sciences|August 7, 2002
Optimizing immunomodulatory therapy for MS patients: an integrated management modelDouglas Jeffery, Khurram Bashir, Linda Buchwald, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 13, 2018
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trialEdward J Fox, Clyde Markowitz, Angela Applebee, et al.
Multiple Sclerosis and Related Disorders|July 22, 2015
Relation of quantitative visual and neurologic outcomes to fatigue in multiple sclerosisSalim Chahin, Deborah Miller, Reiko E Sakai, et al.
Annals of Neurology|April 3, 2008
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trialAmit Bar-Or, Peter A J Calabresi, Douglas Arnold, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 10, 2023
Severe Neuroinvasive West Nile Virus in Association With Anti-CD20 Monotherapy for Multiple SclerosisSimon Thebault, Stephanie Gandelman, Camryn Lane, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|August 16, 2023
Intersite brain MRI volumetric biases persist even in a harmonized multisubject study of multiple sclerosisKelly A Clark, Carly M O'Donnell, Mark A Elliott, et al.
Pageof 3